NUVL vs. TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, and BPMC
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs. Its Competitors
Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Teva Pharmaceutical Industries received 1297 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 67.95% of users gave Teva Pharmaceutical Industries an outperform vote.
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.2% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Nuvalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Nuvalent's return on equity.
Teva Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Teva Pharmaceutical Industries currently has a consensus target price of $24.44, suggesting a potential upside of 38.34%. Nuvalent has a consensus target price of $115.50, suggesting a potential upside of 48.25%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.
In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than Nuvalent. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 5 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.04 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Nuvalent is being referred to more favorably in the news media.
Summary
Teva Pharmaceutical Industries beats Nuvalent on 9 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 6/13/2025 by MarketBeat.com Staff
